Commentary on Article: Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents (NEJM, Nov 21 2019)
A. M. Meer Ahmad *
Meer Ahmad Health Consultancy, A317 Apt Selasih, Jln PJU 10/1C, Damansara Damai, 47380, Petaling Jaya, Selangor, Malaysia.
*Author to whom correspondence should be addressed.
Abstract
In this Letter to the Editor, this author comments on the article in the NEJM (Nov 21 2019) in the above title on the TAK-003 Dengue vaccine Phase III trial from a point of comparing with the predecessor, the CYD-TDV, beside comparing the TAK-003 and Severe dengue, and the TAK-003 and hospitalizations. The author also queries why the vaccine must be a chimeric-vaccine, questions the sample-size in the Phase III trial and questions the Serious Adverse Events reported observed in the trial. He write on Antibody Directed Enhancement in a relation to the TAK-003. The author make Additional Observation and seek certain Explanation.
Keywords: Tetravalent dengue vaccine, TAK-003, CYD-TDV, Phase III trial, efficacy, safety, severe dengue, dengue hospitalization, chimeric vaccine, sample-size, serious side effect, antibody-directed enhancement.